Study guide
10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement
Key Takeaways Explain This Topic AI
A complete mole is usually 46,XX (all paternal DNA) without fetal tissue, with markedly elevated hCG and a 'snowstorm' ultrasound pattern; a partial mole is triploid (69,XXY) with fetal parts.
Molar pregnancy is treated with suction curettage, followed by serial hCG until undetectable plus additional confirmatory values, with reliable contraception during surveillance.
A plateau or rise in hCG after molar evacuation signals gestational trophoblastic neoplasia, which is highly curable with chemotherapy such as methotrexate.
Stillbirth is fetal death at 20 weeks or later; the most useful evaluations are fetal autopsy, placental pathology, and genetic testing (chromosomal microarray), with Kleihauer-Betke and antiphospholipid testing.
Bereavement care includes offering to see and hold the baby, memory-making, lactation suppression guidance, screening for depression and complicated grief, and a plan for future pregnancy.
Last updated: October 2026
Gestational Trophoblastic Disease (GTD)
GTD is a spectrum of abnormal trophoblast proliferation, from benign hydatidiform mole to malignant gestational trophoblastic neoplasia (GTN). Risk is highest at the extremes of reproductive age and with a prior molar pregnancy.
Feature Complete Mole Partial Mole
Karyotype 46,XX (rarely 46,XY), all chromosomes paternal (an "empty" egg fertilized) Triploid (69,XXY or 69,XXX) : one maternal and two paternal sets
- Fetal tissue None Present (often abnormal)
- hCG Often markedly elevated (frequently >100,000 mIU/mL) Often normal or mildly elevated
- Uterine size Often large for dates Often appropriate or small
Ultrasound "Snowstorm" or cluster-of-grapes pattern; theca lutein cysts Focal cystic placental changes with a fetus
Risk of GTN About 15%–20% About 0.5%–5%
Presentation: Vaginal bleeding is most common. High hCG can cause hyperemesis , hyperthyroidism (hCG stimulates the TSH receptor), theca lutein cysts, and preeclampsia before 20 weeks , which should always raise suspicion of a mole.
Management
Suction curettage is the treatment of choice, regardless of uterine size; obtain baseline hCG, CBC, type and screen, and a chest radiograph if GTN is suspected. Give Rh immune globulin to Rh(D)-negative patients (partial moles contain fetal red cells).
hCG surveillance: Measure hCG every 1–2 weeks until undetectable. After a complete mole , obtain additional monthly values (commonly for about 3 months) to confirm it stays undetectable; after a partial mole , one confirmatory normal value a month later is usually enough.
Contraception during surveillance prevents a new pregnancy from confusing the hCG trend. Hormonal methods are safe; an IUD is avoided until hCG is undetectable because of perforation risk with persistent disease.
Gestational Trophoblastic Neoplasia
Suspect GTN when post-evacuation hCG plateaus over about 3 weeks, rises over about 2 weeks, or stays detectable about 6 months, or when choriocarcinoma is found (it can follow any pregnancy and often metastasizes to the lungs). Low-risk GTN is treated with methotrexate (or actinomycin D) and is curable in nearly all patients; high-risk disease receives multi-agent chemotherapy.
Recurrent Pregnancy Loss
ASRM defines recurrent pregnancy loss as two or more clinical pregnancy losses. Evaluation includes:
Parental karyotypes (balanced translocations).
Uterine cavity assessment (septate uterus, submucosal fibroid, synechiae) with sonohysterography, 3D ultrasound, or hysteroscopy.
Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein I), repeated 12 weeks apart if positive.
Endocrine factors: TSH, A1C or glucose, and prolactin when indicated.
About half of cases remain unexplained, yet the chance of a live birth in the next pregnancy is still good, which is an important message for patients. Antiphospholipid syndrome is treated with low-dose aspirin plus prophylactic heparin, and vaginal progesterone may help patients with prior losses who bleed in early pregnancy.
Stillbirth (Intrauterine Fetal Death)
In the United States, stillbirth is fetal death at 20 weeks or later , occurring in about 1 in 175 births. Risk factors include hypertension, diabetes, obesity, smoking, older age, multiple gestation, fetal growth restriction, infection, and placental abruption; Black patients face about twice the rate of White patients.
Diagnosis and Evaluation (ACOG/SMFM)
Confirm absent cardiac activity by ultrasound. The highest-yield tests are:
Fetal autopsy (offer it respectfully; partial or noninvasive options exist).
Placental, cord, and membrane pathology.
Genetic testing , preferably chromosomal microarray on fetal or placental tissue.
Maternal tests: Kleihauer-Betke or flow cytometry for fetomaternal hemorrhage, antiphospholipid antibodies, and others guided by history (syphilis, parvovirus, glucose testing, toxicology).
Delivery Options
Induction of labor (misoprostol, oxytocin, or mechanical ripening) is the most common choice; dilation and evacuation is an option in the second trimester with experienced providers.
Expectant management is reasonable for some patients because most labor within 2 weeks, but prolonged retention beyond about 4 weeks raises the risk of coagulopathy (monitor fibrinogen).
Give Rh immune globulin to Rh(D)-negative patients.
Bereavement Care After Any Pregnancy Loss
Use the baby's name if one is given, and offer, without pressure, the chance to see, hold, bathe, and photograph the baby and to keep mementos such as footprints and a lock of hair.
Provide clear explanations, written information, chaplaincy or cultural support, and help with autopsy and burial decisions.
Lactation may begin after a second- or third-trimester loss: advise a supportive bra, cold compresses, and NSAIDs; some patients choose to donate milk. Cabergoline is used off-label for suppression; bromocriptine is not recommended.
Screen for depression, anxiety, PTSD, and complicated grief at follow-up; partners grieve too and may grieve differently.
Plan the next pregnancy: Review the cause, optimize health, date the pregnancy early, and increase surveillance (serial growth scans and antenatal testing from about 32 weeks), recognizing the anxiety a new pregnancy brings.